A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

Nature

Volumn 428, Issue 6982, 2004, Pages 561-564

  Yang, Zhi Yong ^a   Kong, Wing Pui ^a   Huang, Yue ^a   Roberts, Anjeanette ^a   Murphy, Brian R ^a   Subbarao, Kanta ^a   Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CELLS; DNA; GENES; RESPIRATORY SYSTEM; VIRUSES;

NEUTRALIZATION; SEVERE ACUTE RESPIRATORY SYNDROME (SARS);

MEDICINE;

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

DNA; MEDICINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENETIC CODE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; LUNG; MEASUREMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SARS CORONAVIRUS; T LYMPHOCYTE; VACCINATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY; PHYSIOLOGY; SERODIAGNOSIS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSPLANTATION; VIROLOGY;

ANIMALIA; CORONAVIRUS; RNA VIRUSES; SARS CORONAVIRUS; VECTORS;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; LUNG; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VIRAL VACCINES; VIRUS REPLICATION;

EID: 1842589262     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02463     Document Type: Article

References (23)

1. Ksiazek, T. G. et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953-1966 (2003).
2. Drosten, C. et al. Identification of a novel coronavirus inpatients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967-1976 (2003).
3. Tsang, K. W. et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 548, 1977-1985 (2003).
4. Lee, N. et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 548, 1986-1994 (2003).
5. Poutanen, S. M. et al. Identification of severe acute respiratory syndrome in Canada. N. Engl. J. Med. 348, 1995-2005 (2003).
6. World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). WHO 〈 http://www.who.int/csr/sars/en/WHOconcensus.pdf〉 (2003).
7. Rota, P. A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394-1399 (2003).
8. Marra, M. A. et al. The genome sequence of the SARS-associated coronavirus. Science 300, 1399-1404 (2003).
9. Snijder, E. J. et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991-1004 (2003).
10. Lai, M. M. C. & Holmes, K. V. in Fields Virology (ed. Knipe, D. M.) 1163-1185 (Lippincott, Williams & Wilkins, Philadelphia, 2001).
11. Saif, L. J. Coronavirus immunogens. Vet. Microbiol. 37, 285-297 (1993).
12. Park, S. et al. Immune response of sows vaccinated with attenuated transmissible gastroenteritis virus (TGEV) and recombinant TGEV spike protein vaccines and protection of their suckling pigs against virulent TGEV challenge exposure. Am. J. Vet. Res. 59, 1002-1008 (1998).
13. Sestak, K. et al. Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins. Vet. Immunol. Immunopathol. 70, 203-221 (1999).
14. Holmes, K. V. in Fields Virology (ed. Knipe, D. M.) 1187-1203 (Lippincott Williams & Wilkins, Philadelphia, 2001).
15. Yang, Z.-Y. et al. pH-dependent entry of SARS coronavirus is mediated by the Spike glycoprotein and enhanced by dendritic cell-mediated transfer through DC-SIGN. J. Virol. (in the press).
16. Fouchier, R. A. et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423, 240 (2003).
17. Martina, B. E. et al. Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
18. Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of SARS coronavirus in the respiratory tract of mice. J. Virol. 78, 3572-3577 (2004).
19. Perlman, S. Pathogenesis of coronavirus-induced infections. Review of pathological and immunological aspects. Adv. Exp. Med. Biol. 440, 503-513 (1998).
20. Gurunathan, S., Klinman, D. M. & Seder, R. A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974 (2000).
21. Kong, W. P. et al. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77, 12764-12772 (2003).
22. Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493-497 (1938).
23. Epstein, S. L. et al. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int. Imunol. 12, 91-101 (2000).